Rothera Mark 4
4 · Viracta Therapeutics, Inc. · Filed Sep 19, 2022
Insider Transaction Report
Form 4
Rothera Mark
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2022-09-19+1,375,000→ 1,375,000 totalExercise: $5.21Exp: 2032-09-19→ Common Stock (1,375,000 underlying)
Footnotes (1)
- [F1]Twenty-five percent (25%) of the total shares subject to the Option will vest on the one (1)-year anniversary of the grant date and 1/48th of the total shares subject to the Option will vest each month thereafter on the same day of the month as the grant date (and if there is no corresponding day, the last day of the month), subject to the Reporting Person continuing to be a Service Provider in accordance with the Company's 2021 Inducement Equity Incentive Plan through each such date.